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Abstract
We commonly diagnose ocular diseases via both morphological changes and 
symptoms. It is necessary to develop biochemically based assays for early or follow-
up diagnosis of these diseases with a focus on robustness and ease of handling. 
To lay out a prospective path toward this goal, we describe and propose the use of 
ultrahigh sensitive paper-based ELISA (p-ELISA), which uses a treated piece of 
filter paper to monitor the activity of ocular diseases (i.e., detecting the vascular 
endothelial growth factor (VEGF) concentration in aqueous humour for prolifera-
tive diabetic retinopathy or age-related macular degeneration diagnosis). The 
advantages of p-ELISA include the following: (1) the capacity to directly measure 
biomarker concentrations in aqueous humour using only a tiny sample volume 
(as little as 2 μL); (2) significantly increased sensitivity compared to conventional 
ELISA (fg/mL levels); and (3) inexpensive materials and a short operation dura-
tion. P-ELISA is a novel point-of-care diagnostic tool with the significant potential 
to advance ophthalmological treatment guidelines by facilitating early detection 
and routinely monitoring therapeutic response.
Keywords: paper-based ELISA, VEGF, diagnosis, ocular disease, ophthalmology, 
aqueous humour
1. Introduction
Prevention, diagnosis and treatment are the core principles of modern medical 
care. Two of these principles, prevention and treatment, are inextricably linked to 
the third, precise diagnosis. Suitable early diagnostic criteria must be established 
on properly understanding the pathophysiology of a specific disease and how it 
impacts the human body. Precise diagnosis naturally leads to precise prevention 
and treatment. By developing current biotechnologically relevant technologies, 
medical practitioners will have increasingly adequate tools for precise diagnoses and 
suitable monitoring of treatment methodologies. Most ophthalmologists, however, 
still diagnose ocular diseases based primarily on structural and functional changes. 
In this chapter, we will discuss biochemically based diagnostic tools for ophthal-
mology. The introduction consists of two parts: (1) an introduction to current 
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biochemically based diagnostic tools and the clinical applications of ELISA and 
(2) a discussion on the importance of VEGF monitoring for several eye diseases. 
Following this, we will present an overview and details on paper-based ELISA 
(p-ELISA), a rapid, cost-effective, easy-to-handle, sensitive, and robust method for 
monitoring aqueous humour VEGF level in ocular diseases.
1.1 ELISA in clinical applications
Biochemically based diagnostic tools have been widely used for a variety of 
specific clinical disease diagnoses, prognoses, and the evaluation of treatment 
efficacy. We have used such tools to measure specific tumor biomarkers as part 
of a multiple cancer screening tool (e.g., PSA screening for the prostate cancer), 
and to monitor CRP level to evaluate patient inflammatory state [1]. The focus 
of such biochemically based diagnostic tools is quantification or qualification 
of a target substance in body fluids to assist medical practitioners with precise 
disease diagnosis or treatment status [2]. To distinguish specific substances from 
body fluids, researchers have used multiple strategies including, but not limited 
to, enzyme-catalyzed reactions [3], antibody/antigen interactions, spectropho-
tometry [4], and electrophoresis [5]. Enzyme-catalyzed reactions and antibody/
antigen interactions are two of the most widely applied technologies among 
biochemically based diagnostic tools. In the enzyme-catalyzed reactions model, 
the specific binding capabilities of enzymes facilitate the measurement of enzyme 
catalytic activities as a means of quantifying or qualifying a target substrate [6]. 
Raabo and Therkildsen first applied this strategy to measure blood sugar using 
glucose oxidase (GOD) [3]. In the antibody/antigen interactions model, quantita-
tive capacity is provided by the immunological affinity between an antibody and a 
specific substrate or antigen, one of which is immobilized in the solid phase while 
the other is distributed in the liquid phase. This method is widely used in clinical 
biochemistry (e.g., detection of human chorionic gonadotropin in a pregnancy 
test [7]). Such methods are linked to the development of the enzyme-linked 
immunosorbent assay (ELISA), first described by Engvall and Perlmann, who 
combined the specificity of antibody/antigen interactions with signal amplifica-
tion via high-turnover catalytic enzymes to provide both high sensitivity and 
specificity [8]. ELISA is traditionally performed in a 96-well plastic plate. Current 
formats of ELISA typically include the direct type, indirect type, sandwich type, 
and competitive type, with procedural details for each described in the chapter 
references [9]. The clinical importance of ELISA is the capacity to detect trace 
amounts of a particular peptide or protein (also known as antigen or antibody in 
an ELISA kit) in a rapid and executable way. ELISA is widely used as a screening 
or diagnostic tool. It is used for infectious disease screening, as in the detection of 
human immunodeficiency virus antigen (HIV-Ag) for the diagnosis of acquired 
immune deficiency syndrome (AIDS) [10]. It is employed for toxicology as in 
the detection of organophosphate in wheat end products [11]. And it is used for 
allergen screening in the food industry [12]. Conventional ELISA requires volumes 
of approximately 200 μL for test completion. Unfortunately, fluid sources such as 
aqueous humour are limited, which rules out conventional ELISA methodology for 
ocular disease detection. A modified ELISA, p-ELISA for instance, that could use 
minute sample volumes would be an invaluable tool in such cases.
1.2 Importance of monitoring VEGF levels within the human eye
Measuring the concentrations of specific circulating substrates (e.g., vascular 
endothelial growth factor (VEGF)) in aqueous humour or vitreous humour can pro-
vide ophthalmologists with a relevant tool for evaluating ocular diseases. Elevation 
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of the VEGF plays a critical role in the pathological angiogenesis of age-related mac-
ular degeneration (AMD) and diabetic retinopathy (DR) [13], the two leading causes 
of blindness in developed countries. AMD is a degenerative disease characterized by 
loss of central vision. Clinically, we can classify AMD into neovascular and non-
neovascular types. DR is one of the major complications of type 1 and type 2 diabetes 
mellitus. Over 30 million people suffer from vision-threatening DR worldwide [14]. 
Overexpression of VEGF in neovascular AMD and DR leads to neovascularization 
and vascular leakage, which eventually results in retinal thickening and edema 
[13, 15]. Both of the diseases mentioned above are diagnosed by symptomatic and 
structural examination using an ophthalmoscope, fluorescein angiography (FA), or 
optical coherence tomography (OCT). Both can be treated with intravitreal injection 
of VEGF inhibitors (for neovascular AMD and DR). Injection of anti-VEGF agents 
has become one of the most effective treatments for neovascular AMD and DR 
[16, 17]. Pegaptanib, ranibizumab, bevacizumab and aflibercept are the currently 
available anti-VEGF agents. Although anti-VEGF therapy has saved many patients 
from visual loss, the cost of anti-VEGF therapy is relatively high and requires lifelong 
treatment (e.g., in neovascular AMD, the cost was about €22,818–37,926 per year 
for bevacizumab, ranibizumab, and aflibercept therapy [18]). Unfortunately, the 
efficacy of anti-VEGF therapy varies from person to person, which provokes contro-
versy over treatment time schedules. Individualized therapy is frequently advocated 
but limited by deficient tools to precisely monitor the progression of the pathologi-
cal angiogenesis in eyes. It is commonly known that elevation of VEGF appears 
before clinically detectable structural or functional changes [19]. Clearly then, easy 
detection of VEGF levels within the human eye can decidedly assist early diagnosis, 
severity assessment (as a quantitative tool), and drug-efficacy evaluation.
Both the blood-ocular barrier and insufficient quantities of aqueous humour 
have limited the possibilities for biochemically based diagnostic tools for ocular 
diseases. In most cases, an ophthalmologist can only diagnose and follow up on 
ocular diseases via examination of morphological changes of the eyes and symp-
toms analysis. Unfortunately, anatomical changes and functional visual loss are 
largely, though not completely, irreversible. Therefore, it is necessary to develop 
an early detection technique to diagnose and monitor ocular diseases before visual 
acuity loss, and such a technique must be capable of using only small sample 
amounts. We believe that p-ELISA is just such a tool. It can be used to monitor 
VEGF levels with minute sample amounts and is capable of ultrahigh sensitivity 
and specificity.
2.  How do we apply p-ELISA to monitor VEGF levels in ocular  
diseases?
Although the vitreous humour occupies the majority of the space in the human eye 
(about 4 mL in an adult eye) and contacts directly to the retina, it is difficult to extract 
the vitreous humour as a diagnostic sample for retina evaluation for two reasons: 
(1) the vitreous humour is stagnant and not actively replenished and (2) the risk of 
vitreous hemorrhage and retinal detachment when extracting vitreous humour. Several 
studies have reported that cytokine level in aqueous humour is highly correlated with 
vitreous level and severity of AMD and DR [20, 21]. For this reason, extracting aque-
ous humour is a safer source of material for monitoring VEGF level. Aqueous humour 
is produced from the ciliary process at an average rate of 2.4 μL/min [22] and fills the 
anterior and the posterior chambers. The total volume of an adult’s aqueous humour is 
about 250 μL. The maximum amount of aqueous humour that can be extracted from 
the anterior chamber at one time before potential chamber collapse is approximately 
200 μL.
Novel Diagnostic Methods in Ophthalmology
4
The conventional ELISA plate requires relatively large sample volumes per assay 
(50–200 μL) compared to p-ELISA. Both the tolerance and repeatability of each 
test are restricted by sample volume, so small volumes are obviously problematic. 
While sample volume can be magnified via dilution, sensitivity and specificity are 
consequently diminished [23]. Moreover, complicated incubating and blocking 
steps in conventional ELISA are time-consuming and tedious and lead to a decrease 
in sensitivity and specificity. Conventional ELISA requires modification to more 
practical sample volumes on the scale of microliters, and sensitivity and specificity 
must be preserved or amplified.
P-ELISA requires only a piece of filter paper, and can effectively be used with 
well volumes as low as 3 μL. The high surface-to-volume ratio of cellulose fibers in 
paper greatly reduces reaction time so that a diagnostic procedure can be completed 
within a single hour (compared to approximately 4 h for conventional ELISA). 
P-ELISA also relies on methodology that is different from the conventional ELISA 
sandwich model: it uses an indirect model. Instead of using Avastin, the more tradi-
tional monoclonal antibody, p-ELISA uses HRP-conjugated Avastin. The simplified 
protocol and high affinity between antigen/antibody gives rise to ultrahigh sensitiv-
ity and specificity (fg/mL levels). Furthermore, recording and analyzing p-ELISA 
results can be completed by using a commercial handheld cellphone camera and 
image-processing software. In this way, expensive ELISA plate readers are replaced 
by inexpensive and common technology that allows small-scale laboratories to 
perform ELISA analysis in an easy-to-handle and cost-effective manner.
2.1 Production of the paper plate
P-ELISA was first introduced in 2010 by Chao-Min Cheng [24] who used a 
96-microzone paper plate instead of a traditional plastic well to perform ELISA. His 
first 96-microzone paper plate was made using filter paper processed by photoli-
thography to generate hydrophobic barriers between each test zone. He found that 
three-dimensional (3D) structures of the cellulose fiber network in the test zones 
boosted the reaction rate and reduced the required, effective sample volume to 
only 3 μL. Photolithography allowed mass plate production but required expensive 
equipment and a complicated production process. A less costly and simpler proce-
dure was subsequently found: inkjet printing [25]. Of the various inkjet printing 
methods, wax printing and screen printing were found to be the two best, and now 
most common, strategies to produce 96-microzone paper plates. Wax printing uses 
a commercial wax printer to create hydrophobic patterns on filter paper, and screen 
printing uses commercially available polymer solutions [26, 27]. Both of these two 
methods are flexible, inexpensive, and easy to use.
Wax printing is an easy to execute and effective process for forming test zones 
on paper. The nature of the paper substrate allows for the creation of hydrophilic 
test zones, and the wax, printed in circles, makes defined hydrophobic barriers. The 
result is a sheet of paper with small, defined wells arrayed in a format that mimics 
that of a 96-well plate. This 96-well-plate format was first designed on a computer 
using commercial software (white areas as the hydrophilic test zones and black 
areas as the hydrophobic barriers), and then printed on Whatman qualitative paper 
with a commercial wax printer (Xerox Phaser 8560DN). The wax-printed paper 
was then placed on a hotplate (135°C) to melt the printed wax enough to allow it to 
penetrate all the way from the printed side through to the opposite side of the paper 
[28]. Careful attention was paid to this melting process to avoid heating for too 
long, which would result in the wax spreading out too far from its originally printed 
shape. Typically this process took from 10 to 20 min, but visual observation always 
took precedence over total time if necessary. Alternatively to using a hotplate, an 
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oven could be used for this process, in which case the melting process was shorter 
in length. Test zone creation was visually verified by observing whether or not the 
black wax appeared on the back side of the paper or by placing a drop of water on 
the paper to test the integrity of the printed hydrophobic area. While the format 
of the paper plate test zone was identical to that of a traditional, plastic 96-well 
plate for conventional ELISA (circles of 5 mm in diameter), each well or test zone 
required only 3 μL of solution to fill (see Figure 1). Although a smaller test zone 
would require less sample volume, we chose the conventional 96-well plate format 
to facilitate familiarity and a relationship to standard protocols used in conventional 
laboratories.
2.2 How to perform ELISA on the paper plate
To simplify the ELISA protocol, we used an indirect ELISA model instead of the 
conventional sandwich ELISA model. Our protocol comprised 5 steps as follows:  
(1) antigen immobilization within test zones; (2) blocking the test zones with buffer; 
(3) adding enzyme conjugated detection antibodies; (4) washing away unbound  
antibodies; and (5) adding substrates for a color-producing enzymatic reaction. 
Antigen immobilization was completed via application and physical adsorption, a 
process based on the non-specific interaction between the antigens and the paper 
fibers [29]. This step requires approximately 3 μL of solution and 10 min of drying 
under ambient conditions. Blocking the test zones with the blocking buffer prevented 
nonspecific antibody binding. This step also required approximately 3 μL of solution 
and 10 min of drying. Enzyme-conjugated detection antibodies were added to conju-
gate with the immobilized antigen. Incubation period was dependent on experimental 
design. Washing away the unbound antibodies was completed with a piece of blotting 
Figure 1. 
The schematic of the paper plate production. The pattern of the paper plate was first designed using 
commercial software on a computer, and the pattern was printed onto Whatman qualitative paper using a 
wax printer. In the next step, the printed black wax was heated to melt it through the filter paper using a hot 
plate with the temperature set at approximately 135°C. This created defined hydrophobic barriers surround 
hydrophilic test zones. The pattern of the test zones should be clear on both side of the filter paper in the finished 
product.
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paper placed beneath the paper plate to absorb the washing buffer, or the paper plate 
was shaken in a basin of washing buffer. The final step, adding substrates to initiate 
a color-producing enzymatic reaction with the conjugate enzyme, was performed 
immediately after the washing step. Total processing time for this colorimetric reac-
tion varied from case to case, and some conditions, such as humidity and ambient 
temperature, affected evaporation rate, so controlling such variables is important for 
reducing experimental error. Following chemical processing, colorimetric results can 
be conveniently recorded using a desktop scanner or a commercial cellphone camera 
and then analyzed via software using a linear red-green-blue (RGB) system. Although 
a desktop scanner is the most commonly used analytical device for paper-based diag-
nostic tools due to its high sensitivity, the cellphone camera and application model has 
gained significant popularity due to its portability, convenience, and cost efficiency. 
An image interpretation application (e.g., Petgeia) can be used to analyze the colori-
metric reaction. Moreover, several recent papers have shown that cellphone camera 
analytical results are comparable to those from a desktop scanner [30, 31]. Combining 
the convenience of using a simple paper substrate with a lightweight cellphone camera 
and application dramatically increases the practicality of such an approach for effec-
tive, real-time, point-of-care (POC) diagnostics that can significantly impact health 
outcomes for a number of people, especially those in resource-poor environments.
2.3  Protocol from aqueous humour extraction to aqueous VEGF  
level detection
We can now more easily relate the p-ELISA process to our real-life protocol for 
detecting VEGF levels in aqueous humour. The aqueous humour extraction was 
performed under a normal and proper process. All the patients were examined by 
the slit lamp first to evaluate the condition of anterior chamber, and the anterior 
chamber paracentesis was then performed by the following step: the patient was 
placed in a supine position and all the procedure was done under the microscope. 
Local anesthesia was given by dripping 0.5% proparacaine hydrochloride two 
to three times with an interval of 5 min. The surgical field was spread by the lid 
speculum and the eyeball was fixed at the limbus opposite to the paracentesis site. 
First ocular surface was disinfected by diluted beta-iodine solution for 5 min. Then, 
a 27 gauge needle was inserted through the paralimbal cornea carefully with the tip 
overlying and parallel to the iris. The bevel of the needle should be placed forward 
and carefully avoid hurting the lens. A volume of about 50–100 μL aqueous  
humour was extracted and put into storage for further analysis. 50–100 μL aqueous 
humour would be sufficient for detecting the VEGF level by repeating 20 wells in 
p-ELISA model, which required only 2 μL samples for analysis in each well. After 
sampling, prophylactic antibiotic drop and ointment were given. The whole proce-
dure took less than 10 min to complete. For detecting the VEGF levels in aqueous 
humour, first the VEGF concentration calibration curve was produced by adding 
varying VEGF concentrations from a commercially available VEGF kit into a row 
of test zones. These concentrations ranged from 10−14 g/mL to 10−6 g/mL (n = 8) 
(Figure 2) [32]. The calibration curve was calculated using the Hill equation and 
the coefficient of determination (R2) was found to be 0.9938. The resulting color 
intensity of different VEGF concentrations has an approximately linear relation-
ship without considering the blank value [33]. When testing aqueous humour, we 
reduced the requisite sample volume from 3 to 2 μL due to the limited volumes 
available. After adding 2 μL of patient aqueous humour into several test zones, we 
allowed the sample to dry for 10 min. We then added 2 μL 1% BSA blocking buffer 
into the test zones and waited another 10 min for drying. In the next step, 5 μL of 
0.8 mg/mL horseradish peroxidase (HRP)-conjugated Avastin was added as the 
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antibody, and the plates were incubated for 10 min to allow for conjugation with the 
immobilized VEGF. We then added 2.5 μL of streptavidin to enhance the colori-
metric signal. After washing away the excess antibody with washing buffer, a 2 μL 
solution of 3,3′,5,5′-tetramethylbenzidine (TMB) + H2O2 was added into the test 
zones. This facilitated the enzyme substrate-driven colorimetric reaction with the 
HRP-conjugated Avistin. Resulting colorimetric output signals were dynamically 
recorded using a cellphone camera (from HTC Inc., Taiwan). For comparison, colo-
rimetric results were also scanned using a commercial desktop scanner (EPSON; 
No.:GT-10000+). All images taken by these two optical recording approaches were 
then analyzed with image processing software (Adobe, Photoshop CS5), in order 
to compare the differences from each approach. This process was used to refine 
the more convenient cellphone-based recording system [33]. All procedures are 
performed in a laminar flow hood to prevent environmental bias and took less than 
1 h to complete. The total equipment required in this protocol included several filter 
papers, a commercial wax printer, an oven, a pipetman, a commercial cellphone, 
and a desktop scanner, each of which are accessible and cost-effective. In addition to 
these efficiencies, the requirement of tiny sample volumes contributed to a reduc-
tion in overall cost for each test compared to conventional techniques.
The sensitivity of our p-ELISA to detect VEGF in a buffer system was ~33.7 fg/mL, 
which was outstanding for protein-detection technology and 150 times more 
sensitive than conventional ELISA (~5 pg/mL). The ultrahigh sensitivity of this new 
assay was attributed to several advantageous protocol features. First, we modified 
and prepared the antibody from human recombinant VEGF-A antibody to HRP-
conjugated Avastin, and Avastin was the therapeutic antibody for VEGF, which 
carried high specificity toward VEGF. This therapeutic-based monoclonal antibody 
helped streamline the protocol with upgraded specificity. The HRP-conjugated 
Avastin was made following the protocol provided in an EasyLink HRP Conjugation 
Kit as described in detail in our reference information [33]. Secondly, we deviated 
from the conventional sandwich ELISA protocol to use an indirect ELISA protocol, 
which simplified the complicated blocking and washing steps. Lastly, we replaced 
Figure 2. 
The calibration curve of the of the commercially provided VEGF (kit form) using p-ELISA [34]. Eight 
different concentrations of commercial VEGF ranging from 10−14 g/mL to 10−6 g/mL were used. The calibration 
curve was calculated using the Hill equation, and the coefficient of determination (R2) is 0.9938.
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the alkaline phosphate protocol for our colorimetric response with HRP (colorless 
to blue, instead of purple), allowing us to obtain the stronger output signals. The 
comparison between p-ELISA and conventional ELISA protocol for detecting aque-
ous humour VEGF levels is demonstrated in Table 1.
2.4  Clinical application of p-ELISA to detect VEGF levels in ophthalmological 
patients
In our previous study, we quantified aqueous humour VEGF levels in patients 
with several ocular diseases using p-ELISA. The mean VEGF levels detected in 
13 senile cataract patients was 14.4 ± 8.5 pg/mL (mean ± SD), in 14 patients with 
proliferative DR (PDR), it was 740.1 ± 267.7 pg/mL, in 17 patients with AMD, it 
was 383 ± 155.5 pg/mL, and in 10 patients with retinal vein occlusion (RVO), it was 
219.4 ± 92.1 pg/mL respectively [33]. In one study using conventional ELISA, Jian-
Ping Tong reported that the mean VEGF levels from 10 senile cataract patients was 
108.3 ± 72.3 (mean ± SD) pg/mL, while in 12 patients with choroidal neovascular-
ization due to AMD it was 668.9 ± 340.0 pg/mL [20]. Similarly using conventional 
ELISA, Hideharu Funatsu reported mean VEGF levels of 26 patients with PDR as 
376.5 ± 187.8 [21], and H Noma reported mean VEGF levels from 24 patients with 
branch RVO as 299.1 pg/mL [34]. The pathogenesis of senile cataracts is rooted 
in degenerative effects on lens structure, which is different from the pathological 
angiogenesis of PDR, AMD, and RVO. Therefore, patients with senile cataract 
would be a good control group for our experiment. As we can see from the results 
mentioned above, both the p-ELISA and conventional ELISA showed consider-
able disparity in VEGF levels between patients with senile cataract and patients 
with PDR, AMD, or RVO (the levels of VEGF were low in the senile cataract group 
and high in PDR, AMD, or RVO groups). The aqueous VEGF levels measured by 
P-ELISA for VEGF Conventional ELISA for VEGF
Equipment Paper plate
Desktop scanner
Smartphone camera
Plastic plate
Plate readout
Antigen/primary 
antibody
VEGF/HRP-conjugated avastin VEGF/human recombinant
VEGF-A antibody
Secondary antibody None HRP conjugate
Cost for equipment 100 USD 20,000 USD
Dilution No Yes
Detection sensitivity 0.03 pg 18.75 pg/mL
Detection range 0.01–100,000 pg/mL 31.25–2000 pg/mL
Reagent/duration Volume (μL) Time (mins) Volume (μL) Time (mins)
(1) Immobilize VEGF 2 7 70 120
(2) Blocking 2 7 100 30
(3) Antibody 7.5 20 30 60
(4) Colorimetric reaction 
(add TMB+ H2O2)
2 10 100 3
Total per zone 13.5 44 300 213
Total sample volume 
require per test
40 (repeat 20 
wells)
9600 (total 
96 wells)
Table 1. 
A comparison between conventional ELISA and p-ELISA in the detection of VEGF levels.
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p-ELISA were comparable to those from conventional ELISA, supporting the idea 
that pathological angiogenesis can be adequately diagnosed using p-ELISA. Further 
case studies with greater sample numbers are necessary to confirm this.
In another one of our previous studies, we used p-ELISA to detect aqueous 
humour VEGF levels before and after intravitreal injection (IVI) of anti-VEGF 
antibodies.  
The results showed that the mean VEGF levels in 16 patients with neovascular 
AMD, myopic neovascularization, or polypoidal choroidal vasculopathy were 
545.71 ± 810.29 pg/mL (mean ± SD) before IVI of anti-VEGF antibodies. After IVI of 
anti-VEGF antibodies, the mean VEGF levels became 0.072–0.131 pg/mL (N = 15) 
within 5 weeks and 163.06 ± 367.06 pg/mL (N = 15) after 5 weeks. We also evalu-
ated the efficacy of the ranibizumab and bevacizumab by detecting VEGF levels via 
p-ELISA and found that 50% of patients (6/12) that took ranibizumab demonstrated 
earlier VEGF elevation within 49 days compared to 11.11% (2/18) in patients that 
took bevacizumab (p = 0.0342) [32]. The minimal sample volume requirement and 
ultrahigh sensitivity of p-ELISA allowed us to monitor VEGF levels closely. Using 
this approach, ophthalmologists could prescribe personalized VEGF inhibitor treat-
ment schedules for their patients. In addition, the delicate data output of p-ELISA 
could also assist clinicians and pharmaceutical companies to evaluate the effects of 
anti-VEGF antibodies. In summary, using p-ELISA to monitor aqueous VEGF level 
can be a useful tool to assist diagnosis of several ocular diseases, evaluate treatment 
efficacy of anti-VEGF treatment, and promote the development of new drugs.
Although the IVI of anti-VEGF antibodies has become one of the most powerful 
treatment strategies for patients with pathological angiogenesis in eye diseases, there 
are still many limitations to the clinical application of VEGF inhibitors:  
(1) drug efficacy varies from person to person; (2) the adverse effects of IVI of VEGF  
antibiotics include post-injection endophthalmitis [35, 36], uveitis, rhegmatogenous 
retinal detachment, vitreous hemorrhage [36, 37], and the risk for sustained intraoc-
ular pressure elevation [36, 38]; and (3) the potential of systemic adverse events such 
as an increase in bleeding tendency [36]. Therefore, a good procedure for monitoring 
VEGF levels within the human eye would be beneficial to patients who receive VEGF 
inhibition therapy. In patients with good response to anti-VEGF therapies, a clinical 
ophthalmologist can decrease the frequency of VEGF inhibitor injections based on 
scheduled VEGF level monitoring by p-ELISA. Decreasing the frequency of IVI of 
VEGF antibiotics not only saves unnecessary medical expenses for patients, it spares 
the patients from the risk of therapeutic complications. For those patients with poor 
response to anti-VEGF therapies, early detection of elevated VEGF via ultrasensi-
tive p-ELISA can alert a clinical ophthalmologist to increase treatment frequency or 
change the therapeutic approach. Because elevations in VEGF level appear earlier 
than morphological changes or visual acuity changes, monitoring VEGF levels can 
provide helpful early detection of disease and further prevent undesirable vision 
loss in those afflicted [39] (Figure 3). In addition to being ultrasensitive, p-ELISA 
for VEGF level detection takes only a short time (<1 h) compared to conventional 
ELISA (4–5 h). In a conventional outpatient clinical setting, aqueous humour 
extraction for VEGF level detection requires an initial visit, time-consuming testing, 
and a follow-up visit to discuss possible treatment options. With p-ELISA, a patient 
could be examined and receive results within an hour, hastening and increasing the 
efficacy of possible treatment (schematically described in Figure 4). Using p-ELISA 
for diagnosis as well as follow-up monitoring provides a more effective and less 
costly means of caring for patients without sophisticated laboratories and expensive 
ELISA readers. It offers a truly viable POC device that can be used in rural areas, in 
the developing world, and in emergency or resource-poor environments in ways that 
may revolutionize existing ocular disease diagnosis and treatment.
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2.5 The future prospects of paper-based ELISA
P-ELISA, first developed by the Whitesides Research Group at Harvard 
University to detect IgG and HIV antigen in serum, has become a useful diagnostic 
tool in many medical fields including the diagnosis of infectious disease (e.g., HIV, 
E. coli, and dengue fever [24, 28, 40]), the detection of autoimmune antibodies 
(e.g., anti-noncollagenous 16A (NC16A) in patients with bullous pemphigoid [41]), 
potential tumor marker assessment [42] and human cognitive performance deter-
mination (e.g., detecting specific neuropeptides such as neuropeptide Y following 
traumatic brain injuries and post-traumatic stress disorder [43]). We first used 
p-ELISA in the ophthalmological field to detect VEGF levels in aqueous humour 
and had good results in both disease diagnosis and treatment followed-up. P-ELISA 
is uniquely posed to meet the needs of eye disease diagnosis because it requires only 
tiny sample amounts to provide ultrahigh sensitive results. It is foreseeable that 
p-ELISA will take its place among commonly practiced approaches for diagnosing 
and treating ocular diseases. There are, in fact a great many detectable cytokines 
and growth factors in aqueous humour besides VEGF including tumor necrosis 
factor (TNF)-α, interleukin (IL)-2, -4, -5, -6, -8, -10, serum amyloid A (SAA), 
and migration inhibitory factor (MIF), and p-ELISA may ultimately be useful 
for detecting each of them. The elevation or depression of each of these markers 
is associated with ocular disease states [44–47]. It is worth noting that could the 
capacity to analyze a host of biomarkers with only tiny amounts (2 μL) of aqueous 
humour could lead to a comprehensive optical health examination that goes beyond 
and is more impactful than existing morphological and functional examinations.
As bright as the future is for this novel diagnostic technology, there are still 
existing limitations. Aqueous humour sampling is invasive, and low volume 
extraction does not eliminate risks of infection, hyphema, or lens capsule 
rupture. A less invasive strategy for evaluating ocular diseases would be ideal. 
We do know that tears carry a number of cytokines that are highly correlated 
with corneal and conjunctival disease. Elevation of IL-6, IL-8, and VEGF appears 
Figure 3. 
The correlation between elevated VEGF, structural change, and vision impairment in patients receiving anti-
VEGF therapy [39]. The Y coordinates represent VEGF levels, the structural changes, and vision impairment. 
The X coordinates represent the time sequence after the injection of anti-VEGF agent. Once the effects of the 
anti-VEGF agent began to wear off, VEGF levels initially elevated, leading to pathological angiogenesis, retinal 
structural changes, and vision impairment. Using an ultra-sensitive device such as p-ELISA to detect elevated 
VEGF levels would reduce the likelihood of structural changes and vision impairment. (a) P-ELISA or other 
POC diagnostics can detect elevated VEGF levels in the first disease progression sequence. (b) The structural 
changes could be noticed by FAG or OCT after a time lag of approximately 16 days following initial VEGF 
elevation. (c) Vision impairment would follow soon after the structural changes occurred.
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in patients with corneal neovascularization [48]. Elevation of inflammatory 
cytokines (IL-1β, IL-6, INF-γ, and TNF-α) indicates inflammation from ocular 
surface diseases [49, 50]. Detection of the trace amounts of biomarkers in tears 
by using ultra-sensitive p-ELISA is a direction for further investigation. P-ELISA 
has greatly simplified the complicated steps of conventional ELISA and elimi-
nated the need for expensive equipment, but the process still requires profes-
sional medical technologists and simple laboratories for analyzing results, at 
least until cellphone camera applications become more developed. The properties 
of the p-ELISA as a lab-on-paper device make it a promising future POC device. 
Further modifying p-ELISA devices from an ophthalmologist-friendly diagnostic 
tool to a patient-friendly POC device remains a challenge. Development of an in 
situ device for ophthalmological analysis would provide considerable healthcare 
impact in developing countries with limited resources and alleviate the currently 
unbalanced ophthalmologist to patient ratio. This paper-based diagnostic tool 
is easy to handle, fast, sensitive, and requires only small samples and simple 
equipment to quantity specific biomarkers. P-ELISA has the potential to provide 
impactful benefit in the evaluation of ocular diseases and improve ocular health 
in real world.
3. Conclusions
In this chapter, we described how paper-based ELISA (p-ELISA) was robust, 
user-friendly, and required only small sample amounts (e.g., 2 μL of aqueous 
humour to measure VEGF) to return results that demonstrated very high sensitivity 
(~33.7 fg/mL). Detection of aqueous humour VEGF level via p-ELISA provides not 
only early diagnosis of ocular diseases with pathological angiogenesis (e.g., PDR, 
Figure 4. 
The 3 different outpatient clinic scenarios for the follow-up examination of the patients receiving anti-VEGF 
treatment [39]. (a) Optical imaging modalities: the patient receives the optical imaging test only to determine 
whether to receive anti-VEGF treatment or observation. (b) Optical imaging + conventional ELISA VEGF 
level test: the patient receives the optical imaging test and extraction of aqueous humour occurs at the first visit. 
Because the conventional ELISA requires 4–5 hours to finish, the patient must arrange another appointment 
with the doctor to see the reports and decide whether to receive the anti-VEGF treatment. The next visit is 
usually one week later. This modality provides more information but has the risk of delaying treatment. (c) 
Optical imaging + p-ELISA VEGF level test: the patient receives the aqueous humour extraction, sees the testing 
reports, and decides whether to receive the treatments immediately within one visit. The short testing time of 
p-ELISA (<1 hr) allows the patient to obtain timely and proper treatment.
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AMD, and RVO), but assists in outlining accurate disease treatment. In regards to its 
effect on ocular disease diagnosis and treatment, p-ELISA can provide precise and 
quantitative biochemical data prior to the onset of morphological and functional 
changes. An early diagnosis could lead to early treatments and save patients from 
undesirable visual loss. As an aid to treatment monitoring, p-ELISA can record the 
efficacy of anti-VEGF therapy based on continuous follow-up measurement of VEGF 
level in aqueous humour. In this way, clinical ophthalmologists could provide ideal 
and individualized treatment schedules for different patients. Furthermore, this 
cost-effective and portable diagnostic device could provide far reaching and effec-
tive ocular health care for underserved populations especially in developing coun-
tries. P-ELISA is a simple diagnostic device that may well widen our views on eyes.
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